drugset / Trial / NCT00215553

KL₄Surfactant Treatment in Patients With ARDS

NCT00215553

Phase 2 Terminated 124 enrolled Windtree Therapeutics
RandomizedParallel-groupOpen-labelTreatment

Summary

Lung wash with KL₄Surfactant of individual lung segments using a bronchoscope compared to usual care alone consisting primarily of assisted (mechanical) ventilation in patients with acute respiratory distress syndrome(ARDS).

Timeline

Start
2001-05
Primary completion
2006-02
Completion
2006-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Lucinactant Peptide 5 mg/ml Other
Subject Lucinactant Peptide 10 mg/ml Other
Subject Lucinactant Peptide 20 mg/ml Other